Opus Genetics IRD Cash Provided by (Used in) Investing Activity, Including Discontinued Operation
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation at other companies
Other financials
Where this comes from
Reported directly by Opus Genetics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The official record: Opus Genetics’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Opus Genetics's cash provided by (used in) investing activity, including discontinued operation.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Opus Genetics's cash provided by (used in) investing activity, including discontinued operation?
- Opus Genetics (IRD) reported cash provided by (used in) investing activity, including discontinued operation of $0 in Q1 2026.
- What is the long-term trend for Opus Genetics's cash provided by (used in) investing activity, including discontinued operation?
- Over 4 years (2021 to 2025), Opus Genetics's cash provided by (used in) investing activity, including discontinued operation has grown at a -100.0% compound annual growth rate (CAGR), from -$100K to $0.
- What does cash provided by (used in) investing activity, including discontinued operation mean?
- The total net cash flow resulting from all investing activities, including capital expenditures, acquisitions, and the purchase or sale of securities. It serves as a primary indicator of how much capital the company is reinvesting into its long-term growth and asset base.